Title:
ANTI-PD-1 ANTIBODIES
Document Type and Number:
WIPO Patent Application WO/2018/087143
Kind Code:
A3
Abstract:
The present invention relates to antibodies that bind to PD-1. The invention also relates to immunoconjugates and compositions comprising such antibodies. The invention also provides methods of producing such antibodies. The invention further provides the use of such antibodies for therapeutic and diagnostic purposes.
Inventors:
DUNCAN ALEX (GB)
MCCOURT MATTHEW (GB)
DYSON MICHAEL (GB)
BLACKWOOD JOHN (GB)
MCCOURT MATTHEW (GB)
DYSON MICHAEL (GB)
BLACKWOOD JOHN (GB)
Application Number:
PCT/EP2017/078595
Publication Date:
December 13, 2018
Filing Date:
November 08, 2017
Export Citation:
Assignee:
ACTIGEN LTD (GB)
International Classes:
C07K16/28
Domestic Patent References:
| WO2016113556A1 | 2016-07-21 |
Other References:
TERESA C. LONGORIA ET AL: "Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma", EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, vol. 12, no. 10, 16 August 2016 (2016-08-16), GB, pages 1247 - 1253, XP055516478, ISSN: 1742-5255, DOI: 10.1080/17425255.2016.1216976
C. WANG ET AL: "In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates", CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 9, 28 May 2014 (2014-05-28), pages 846 - 856, XP055206944, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-14-0040
KATHLEEN M. MAHONEY ET AL: "The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma", CLINICAL THERAPEUTICS., vol. 37, no. 4, 1 April 2015 (2015-04-01), US, pages 764 - 782, XP055285031, ISSN: 0149-2918, DOI: 10.1016/j.clinthera.2015.02.018
ROY L MAUTE ET AL: "Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,, vol. 112, no. 47, 1 November 2015 (2015-11-01), pages E6506 - E6514, XP002772779, ISSN: 0027-8424, DOI: 10.1073/PNAS.1519623112
C. WANG ET AL: "In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates", CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 9, 28 May 2014 (2014-05-28), pages 846 - 856, XP055206944, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-14-0040
KATHLEEN M. MAHONEY ET AL: "The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma", CLINICAL THERAPEUTICS., vol. 37, no. 4, 1 April 2015 (2015-04-01), US, pages 764 - 782, XP055285031, ISSN: 0149-2918, DOI: 10.1016/j.clinthera.2015.02.018
ROY L MAUTE ET AL: "Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,, vol. 112, no. 47, 1 November 2015 (2015-11-01), pages E6506 - E6514, XP002772779, ISSN: 0027-8424, DOI: 10.1073/PNAS.1519623112
Attorney, Agent or Firm:
OWEN, Deborah (GB)
Download PDF: